



THE LAW OFFICES OF M. AMBER BARGER, PLLC

3901 Arlington Highlands Blvd., Suite 200, Arlington, TX 76018
abarger@mablawoffice.com • (682) 888-1748

VIA ELECTRONIC MAIL

OTC Markets Group Inc.
304 Hudson Street, 2nd Floor
New York, NY 10013

Re: Attorney Letter with Respect to Current Information - PRTT

April 27, 2020

To Whom It May Concern:

This office has been retained by Protect Pharmaceutical Corporation, Inc., a Wyoming Corporation, with its principal office located at Orešje nad Sevnico 10, 8290 Sevnica, Slovenia (the "Issuer") for the specific purpose of rendering this letter. Only OTC Markets Group is entitled to rely on this letter and publish in determining whether it has made adequate current information publicly available on its website within the meaning of Rule 144(c)(2) under the Securities Act of 1933. OTC Markets Group is granted full and complete permission and rights to publish this letter through the OTC Disclosure & News Service for public viewing.

I am a U.S. Resident and licensed to practice law in the states of Texas and Oklahoma. I am permitted to practice before the Securities and Exchange Commission (SEC) and have not, at any time, been prohibited from practice thereunder. The jurisdictions covered by this letter include the laws of the United States of America. I have not currently, nor have been in the past five years, suspended or barred from practicing in any state or jurisdiction, nor charged in a civil or criminal case. I am not currently, nor have I been in the past five years, been the subject of an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or regulatory agency.

I am independent counsel retained solely for the purpose of reviewing the current information supplied by the issuer. I do not beneficially own any shares of the Issuer's securities. I have not received, nor have an agreement to receive in the future, shares of the Issuer's stock, in payment for services.

I have examined such corporate records and other documents, and such questions of law that I have considered necessary or appropriate for the purposes of rendering this letter. The documents that I have reviewed ("Information") include, but are not limited to:

- a) The Issuer's Financial Statement for 2018;
- b) The Issuer's Financial Statement for 2019; and
- c) The Issuer's Disclosure Statement for Year End December 31, 2019, submitted to OTC on April 23, 2020.

As to matters of fact, I have relied on information obtained from public officials, officers and directors of the Issuer and other source, and these sources are believed to be reliable. In examining the Information, I have assumed that:

- 1) All statements and representations contained therein were accurate and reliable;
- 2) All signatures contained therein were genuine;
- 3) All documents submitted to me were true and accurate copies; and
- 4) All natural persons who signed documents had the legal capacity to do so.

Based on the foregoing review and other matters set forth herein, it is my opinion that the Information (i) constitutes "adequate current public information" concerning the Securities and the Issuer; (ii) has been made publicly available within the meaning of Rule 144(c)(2) under the Securities Act; (iii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"); (iv) complies as to form with the OTC Markets Group's Pink Basic Disclosure Guidelines; and (v) has been posted through the OTC Disclosure & News Service.

The individual responsible for the preparation of the Disclosure Statement and Financial Statements contained in the Information was Zdravko Mastnak, President of Protect Pharmaceutical Corporation, Inc. Mr. Mastnak has served as the President and CEO of Vinska Klet Winery for over ten years as well as military service. The financial statements are not audited, and were prepared by a professional accountant trained at Price-Waterhouse-Coopers.

The Issuer's transfer agent is ClearTrust, LLC, which is registered with the Securities and Exchange Commission. I relied upon information provided by ClearTrust, LLC to confirm the number of outstanding shares set forth in the Information.

I have personally communicated with Mr. Mastnak], who constitutes Issuer management and the sole director, and discussed the Information with the same.

To the best of my knowledge, after inquiry of management and the directors of the Issuer, the Issuer, nor any 5% holder, nor counsel, is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

Neither the Issuer, nor its predecessors, is or ever was a "shell company" as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934.

No person other than the OTC Markets Group is entitled to rely on this letter; however, OTC Markets Group is granted full and complete permission and rights to publish the letter through the OTC Disclosure & News Service for public viewing.

This letter is meant to cover and speak in regard to the Issuer's fiscal year 2018 and 2019 only and shall not apply for any other period.

Yours Truly,



M. Amber Barger
Attorney at Law